The rapid adoption of GLP-1 receptor agonists is reshaping strategic R&D investment across the biopharmaceutical sector, forcing legacy therapeutic programs to demonstrate clear comparative value.
Manufacturing Scale and Yields
Peptide synthesis capacity remains restricted globally. Top producers are committing tens of billions in greenfield plant construction to meet non-metabolic clinical trial requirements.
Payer Reimbursement Restructuring
Health insurers and government health systems are introducing stringent body-mass and comorbidity thresholds to control expanding prescription spending.